ICSE China to offer inaugural conference programme in 2011
Conference series will address global pharma issues such as new drug discovery, biopharm, biosimilars, CRO/CMO, API sourcing, generics and export strategies
ICSE China, which is dedicated to pharmaceutical contract services and outsourcing and will take place from 21 – 23 June 2011 at the SNIEC China, will feature a conference series, titled ‘Pharma R&D and Collaboration Strategies’, says leading events organiser UBM Live.
The inaugural China conference series will address global pharmaceutical issues, with an emphasis on China’s pharma market, across key areas such as new drug discovery, biopharm, biosimilars, CRO/CMO, API sourcing, generics and export strategies and more. It will bring together Chinese and global pharma companies to explore different views regarding the China pharmaceutical market.
Thirty eminent speakers from international pharmaceutical companies and research institutes, such as the FDA, Novartis, USP-China, Roche R&D Center, GSK China/HK, AstraZeneca Innovation Centre China, Sanofi-Aventis, REVA PHARMA, Dr. Reddy's and Shanghai Pharma, will share their knowledge and research strategies. Additionally, in-depth case studies covering r&d and business development strategies will be presented by an outstanding panel of Chinese, Indian and international speakers from industry leading companies and associations.
ICSE China is part of the most international pharmaceutical events line-up in China, which includes CPhI China for pharmaceutical ingredients, P-MEC China for pharma machinery and equipment, BioPh China for the biopharmaceuticals market and the new LABWorld pavilion for laboratory, analytical and biotechnology instrumentation technologies. More than 2,000 exhibitors and 27,000 visitors are expected over the three days. Attendance at the events is free through pre-registration at www.cphi-china.com.
‘China’s domestic market is expected to overtake Japan and become the world’s second drug market by 2015,’1 noted Haf Cennydd, Brand Director, ICSE, P-MEC China and BioPh China. ‘This continued growth has translated into continuously improving results for our events and has enabled us to constantly evolve our brands to reflect market trends. For this year’s events we are excited to introduce a conference programme which will add even greater value for our visitors.’
The introduction of the conference programme to the China events follows the successful launch of a similar series at the CPhI Worldwide, CPhI South America and CPhI India events and is expected to draw more than 400 attendees. The series will be offered in seven individually bookable 3-hour modules and further information can be found at www.cphichina-conference.com.
reference
1. ARC China December 4, 2010 Newsletter
